PPCS

Across TCGA pan-cancer cohorts, PPCS Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PPCS data layer compared with 20 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PPCS Mutation is associated with better overall survival. In most high-consensus cancer types, elevated PPCS expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

BLCA, LUSC, and PRAD are the cancer types where PPCS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.506	0.285	.001	10	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.489	.039	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PPCS–BLCA (OS)

Open the BLCA breakdown →